Literature DB >> 19898425

AID protein expression in chronic lymphocytic leukemia/small lymphocytic lymphoma is associated with poor prognosis and complex genetic alterations.

Mona Leuenberger1, Simona Frigerio, Peter J Wild, Franziska Noetzli, Dimitri Korol, Dieter R Zimmermann, Carole Gengler, Nicole M Probst-Hensch, Holger Moch, Marianne Tinguely.   

Abstract

The biological behavior of chronic lymphocytic leukemia and small lymphocytic lymphoma is unpredictable. Nonetheless, non-mutated IgV(H) gene rearrangement, ATM (11q22-23) and p53 (17p13) deletion are recognized as unfavorable prognosticators in chronic lymphocytic leukemia. The mRNA expression of activation-induced cytidine deaminase (AID), an enzyme indispensable for somatic hypermutation processes, was claimed to be predictive of non-mutated chronic lymphocytic leukemia cells in blood. Here, we evaluated AID protein expression compared with known molecular and immunohistochemical prognostic indicators in 71 chronic lymphocytic leukemia/small lymphocytic lymphoma patients using a tissue microarray approach. We found AID heterogeneously expressed in tumor cells as shown by colocalization analysis for CD5 and CD23. Ki-67 positive paraimmunoblasts of the proliferation centers displayed the highest expression. This observation is reflected by a significant association of AID positivity with a high proliferation rate (P=0.012). ATM deletion was detected in 10% (6/63) of patients and p53 deletion in 19% (13/67) of patients. Moreover, both ATM (P=0.002) and p53 deletion (P=0.004) were significantly associated with AID. IgV(H) gene mutation was seen in 45% (27/60) of patients. Twenty-five percent (17/69) of patients with AID-positive chronic lymphocytic leukemia/small lymphocytic lymphoma displayed a shorter survival than AID-negative chronic lymphocytic leukemia/small lymphocytic lymphoma patients (61 vs 130 months, P=0.001). Although there was a trend, we could not show an association with the IgV(H) gene mutation status. Taken together, our study shows that AID expression is an indicator of an unfavorable prognosis in chronic lymphocytic leukemia/small lymphocytic lymphoma patients, although it is not a surrogate marker for the IgV(H) status. Furthermore, the microenvironment of proliferation centers seems to influence AID regulation and might be an initiating factor in its transformation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19898425     DOI: 10.1038/modpathol.2009.156

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  12 in total

1.  Nonimmunoglobulin target loci of activation-induced cytidine deaminase (AID) share unique features with immunoglobulin genes.

Authors:  Lucia Kato; Nasim A Begum; A Maxwell Burroughs; Tomomitsu Doi; Jun Kawai; Carsten O Daub; Takahisa Kawaguchi; Fumihiko Matsuda; Yoshihide Hayashizaki; Tasuku Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

2.  New developments in the pathology of malignant lymphoma: a review of the literature published from October 2009 to January 2010.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2010-06-02       Impact factor: 0.196

3.  Chronic lymphocytic leukemia cells diversify and differentiate in vivo via a nonclassical Th1-dependent, Bcl-6-deficient process.

Authors:  Piers E M Patten; Gerardo Ferrer; Shih-Shih Chen; Rita Simone; Sonia Marsilio; Xiao-Jie Yan; Zachary Gitto; Chaohui Yuan; Jonathan E Kolitz; Jacqueline Barrientos; Steven L Allen; Kanti R Rai; Thomas MacCarthy; Charles C Chu; Nicholas Chiorazzi
Journal:  JCI Insight       Date:  2016-04-07

4.  Expression of activation-induced cytidine deaminase is associated with a poor prognosis of diffuse large B cell lymphoma patients treated with CHOP-based chemotherapy.

Authors:  Kiyoko Kawamura; Akihiko Wada; Ji-Yang Wang; Quanhai Li; Akihiro Ishii; Hideki Tsujimura; Toshiyuki Takagi; Makiko Itami; Yuji Tada; Koichiro Tatsumi; Hideaki Shimada; Kenzo Hiroshima; Masatoshi Tagawa
Journal:  J Cancer Res Clin Oncol       Date:  2015-06-16       Impact factor: 4.553

5.  IGHV-unmutated and IGHV-mutated chronic lymphocytic leukemia cells produce activation-induced deaminase protein with a full range of biologic functions.

Authors:  Piers E M Patten; Charles C Chu; Emilia Albesiano; Rajendra N Damle; Xiao-Jie Yan; Dorothy Kim; Lu Zhang; Amanda R Magli; Jacqueline Barrientos; Jonathan E Kolitz; Steven L Allen; Kanti R Rai; Sergio Roa; Patricia K Mongini; Thomas MacCarthy; Matthew D Scharff; Nicholas Chiorazzi
Journal:  Blood       Date:  2012-10-15       Impact factor: 22.113

6.  Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia.

Authors:  Pablo Elías Morande; Mariela Sivina; Angimar Uriepero; Noé Seija; Catalina Berca; Pablo Fresia; Ana Inés Landoni; Javier M Di Noia; Jan A Burger; Pablo Oppezzo
Journal:  Blood       Date:  2019-02-27       Impact factor: 25.476

7.  AID downregulation is a novel function of the DNMT inhibitor 5-aza-deoxycytidine.

Authors:  Chiou-Tsun Tsai; Pei-Ming Yang; Ting-Rong Chern; Shu-Hui Chuang; Jung-Hsin Lin; Lars Klemm; Markus Müschen; Ching-Chow Chen
Journal:  Oncotarget       Date:  2014-01-15

8.  Activation-induced deaminase and its splice variants associate with trisomy 12 in chronic lymphocytic leukemia.

Authors:  Kristina Zaprazna; Kamila Reblova; Veronika Svobodova; Lenka Radova; Vojtech Bystry; Jiri Baloun; Kristina Durechova; Nikola Tom; Tomas Loja; Martina Buresova; Kamila Stranska; Alexandra Oltova; Michael Doubek; Michael L Atchison; Martin Trbusek; Jitka Malcikova; Sarka Pospisilova
Journal:  Ann Hematol       Date:  2018-10-27       Impact factor: 3.673

Review 9.  AID in Chronic Lymphocytic Leukemia: Induction and Action During Disease Progression.

Authors:  Pablo Oppezzo; Marcelo Navarrete; Nicholas Chiorazzi
Journal:  Front Oncol       Date:  2021-05-10       Impact factor: 6.244

10.  AID induces intraclonal diversity and genomic damage in CD86(+) chronic lymphocytic leukemia cells.

Authors:  Michael Huemer; Stefan Rebhandl; Nadja Zaborsky; Franz J Gassner; Stefan Hainzl; Lukas Weiss; Daniel Hebenstreit; Richard Greil; Roland Geisberger
Journal:  Eur J Immunol       Date:  2014-10-18       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.